Diversity in Phase 2 and Phase 3 Placebo‐Controlled, Double‐Blind, Lecanemab and Elenbecestat Early Alzheimer’s Disease Studies

Increasing diversity in clinical trials is a scientific, public health, and ethical imperative. Clinicians need to understand how a drug works in representative disease populations, diverse communities need access to clinical trials, and social justice demands addressing health and healthcare disparities. Several factors contribute to underrepresentation among racial and ethnic groups in Alzheimer’s disease (AD) clinical trials, including barriers to enrollment but also potential differential exclusion based on eligibility criteria.